phenylglucoside: RN given refers to (beta-(D))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 65080 |
CHEMBL ID | 4105357 |
CHEBI ID | 8083 |
SCHEMBL ID | 1004929 |
MeSH ID | M0484467 |
Synonym |
---|
bdbm36025 |
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxy-tetrahydropyran-3,4,5-triol |
.beta.-d-glucopyranoside, phenyl |
beta-d-glucopyranoside, phenyl |
phenyl beta-d-glucoside |
einecs 215-978-6 |
phenol glucoside |
glucopyranoside, phenyl-, beta-d- |
brn 0087517 |
1464-44-4 |
aryl beta-d-glucoside |
C03097 |
phenylglucoside |
phenyl beta-d-glucopyranoside |
phenyl beta-d-glucopyranoside, 97% |
phenyl-beta-d-glucopyranoside |
phenyl-beta-d-glucoside |
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxyoxane-3,4,5-triol |
BMSE000770 |
HMS1614E16 |
P0178 |
mfcd00204281 |
AKOS001669140 |
4w3pgi3766 , |
unii-4w3pgi3766 |
5-17-07-00046 (beilstein handbook reference) |
phenyl .beta.-d-glucoside |
glucopyranoside, phenyl-, .beta.-d- |
phenyl .beta.-d-glucopyranoside |
SCHEMBL1004929 |
CHEBI:8083 |
c12h16o6 |
phenyl-.beta.-d-glucopyranoside |
phenyl-.beta.-d-glucoside |
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxytetrahydro-2h-pyran-3,4,5-triol |
CCG-249827 |
AS-59078 |
NCGC00385978-01 |
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxy-tetrahydro-2h-pyran-3,4,5-triol |
Q27107738 |
CHEMBL4105357 |
D82047 |
DTXSID40883677 |
A884507 |
phenyl beta -d-glucopyranoside |
CS-W012565 |
gtpl12455 |
HY-W011849 |
phenyl-(c)micro-d-glucopyranoside |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Excerpt | Relevance | Reference |
---|---|---|
"The metabolic fates of 14C-phenol and its model plant conjugates 14C-phenyl glucoside and 14C-phenyl 6-O-malonyl-glucoside have been compared following equimolar oral dosing to rats (1." | ( A comparison of the metabolic fate of phenol, phenyl glucoside and phenyl 6-O-malonyl-glucoside in the rat. Edwards, VT; Hutson, DH; Jones, BC, 1986) | 0.27 |
Class | Description |
---|---|
glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
glycogen degradation I | 8 | 50 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Taste receptor type 2 member 16 | Homo sapiens (human) | EC50 (µMol) | 482.0920 | 0.0049 | 0.1550 | 0.2500 | AID1618141; AID1619328; AID1619330; AID1619458; AID1619466 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
detection of chemical stimulus involved in sensory perception of bitter taste | Taste receptor type 2 member 16 | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Taste receptor type 2 member 16 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein-coupled receptor activity | Taste receptor type 2 member 16 | Homo sapiens (human) |
protein binding | Taste receptor type 2 member 16 | Homo sapiens (human) |
bitter taste receptor activity | Taste receptor type 2 member 16 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
endoplasmic reticulum | Taste receptor type 2 member 16 | Homo sapiens (human) |
trans-Golgi network | Taste receptor type 2 member 16 | Homo sapiens (human) |
plasma membrane | Taste receptor type 2 member 16 | Homo sapiens (human) |
external side of plasma membrane | Taste receptor type 2 member 16 | Homo sapiens (human) |
membrane | Taste receptor type 2 member 16 | Homo sapiens (human) |
membrane | Taste receptor type 2 member 16 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1439304 | Inhibition of Ascaris suum T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dye b | 2017 | European journal of medicinal chemistry, Mar-10, Volume: 128 | Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. |
AID1439303 | Inhibition of Brugia malayi T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dye | 2017 | European journal of medicinal chemistry, Mar-10, Volume: 128 | Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. |
AID1439305 | Inhibition of Mycobacterium tuberculosis T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioM | 2017 | European journal of medicinal chemistry, Mar-10, Volume: 128 | Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. |
AID1439306 | Inhibition of Shigella boydii T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dy | 2017 | European journal of medicinal chemistry, Mar-10, Volume: 128 | Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. |
AID1439307 | Inhibition of Salmonella typhimurium T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol g | 2017 | European journal of medicinal chemistry, Mar-10, Volume: 128 | Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (12.50) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.61) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |